Annovis Bio, Inc. (07X.F)
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
1.51+0.03%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-35.7%
The outlook
Annovis Bio, Inc. currently reads as bearish based on below its 50- & 200-day averages, 5% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Market cap
$64.2M
52-wk high
4.61
52-wk low
1.35
50-day avg
1.58
200-day avg
2.17
Trailing P/E
—